Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERIFY: Rusfertide in Polycythemia Vera
NCT05210790Phase 3Active, not recruiting
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Apr 2022
- Primary completion
- Feb 2025
- Modality
- Peptides
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in polycythemia vera (PV) comparing Placebo -> Rusfertide with Rusfertide Continuous (2 arms). Primary endpoint: Percentage of Participants Who Achieved Response. Started Apr 2022; status: active, not recruiting.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05210790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210790.